August Troendle Sells 4,000 Shares of Medpace (NASDAQ:MEDP) Stock

Key Points

• CEO August Troendle sold 4,000 Medpace shares at an average price of $620.03, generating $2.48 million; he retains 540,544 shares worth approximately $335.2 million.
• Medpace shares fell 1.2% to $611.57, though the company reported strong quarterly results, including $4.25 EPS and $707.33 million in revenue, up 17.2% year over year.
• Institutional investors own 77.98% of Medpace, while Wall Street maintains a consensus “Hold” rating with an average price target of $584.18.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 4,000 shares of the company's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the completion of the transaction, the chief executive officer owned 540,544 shares of the company's stock, valued at approximately $335,153,496.32. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Medpace Trading Down 1.2%

MEDP traded down $7.48 during trading hours on Thursday, hitting $611.57. The company's stock had a trading volume of 198,148 shares, compared to its average volume of 344,156. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market capitalization of $17.07 billion, a PE ratio of 35.85, a PEG ratio of 2.74 and a beta of 1.15. The company has a 50-day simple moving average of $559.49 and a 200 day simple moving average of $493.31.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 EPS. Medpace's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently modified their holdings of MEDP. California State Teachers Retirement System raised its holdings in Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock worth $7,408,778,000 after buying an additional 13,963,607 shares during the period. BlackRock Inc. purchased a new position in shares of Medpace in the second quarter worth approximately $1,323,047,000. AQR Capital Management LLC increased its position in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock worth $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research analyst reports. Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Robert W. Baird boosted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source